Novavax’s Covid-19 vaccine, already available for use in 170 countries and most well-known for being a non-mRNA vaccine alternative, could be approved for use in the U.S. in February and in up to 10 other countries within 90 days, CEO Stanley Erck told CNBC Monday. Read More: https://www.forbes.com/sites/zacharysmith/2022/01/10/us-could-authorize-novavax-covid-vaccine-an-mrna-alternative-in-february-ceo-says/?sh=134896c12191&utm_source=FBPAGE&utm_medium=social &utm_campaign=forbes | Forbes